Zoetis (NYSE:ZTS) Price Target Lowered to $80.00 at Piper Sandler

Zoetis (NYSE:ZTS) had its target price decreased by equities researchers at Piper Sandler from $90.00 to $80.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 7.47% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday. TD Cowen lowered their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. JPMorgan Chase & Co. dropped their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, UBS Group reduced their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $110.92.

Zoetis Stock Performance

ZTS traded up $1.78 during midday trading on Monday, hitting $74.44. 5,889,951 shares of the company traded hands, compared to its average volume of 5,794,792. The company’s 50-day moving average is $76.66 and its 200 day moving average is $100.58. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market capitalization of $31.21 billion, a PE ratio of 12.27, a price-to-earnings-growth ratio of 1.21 and a beta of 0.73. Zoetis has a 52 week low of $71.45 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the business posted $1.76 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis will post 6.43 EPS for the current year.

Insider Buying and Selling at Zoetis

In related news, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.22% of the company’s stock.

Institutional Trading of Zoetis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Zoetis in the second quarter worth $25,000. Dunhill Financial LLC boosted its stake in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the period. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis during the first quarter worth about $28,000. Finally, Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.